MET and cancer: For instance, MET whose activation is related to resistance to epidermal growth factor receptor inhibitors [108], PDGFRB whose inhibition is associated with an improved tumor drug uptake [109], CLU that interferes with apoptotic signaling and confers resistance to a broad spectrum of anti-cancer treatments [110,111], and ASNS involved in resistance to L-asparaginase [56,112].